Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Syneos Health Inc    SYNH

SYNEOS HEALTH INC (SYNH)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Syneos Health Schedules Second Quarter 2018 Earnings Call for Thursday, August 2, 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/13/2018 | 12:03am CEST

RALEIGH, N.C., July 12, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO (Contract Commercial Organization), will release its second quarter 2018 financial results on Thursday, August 2, 2018, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 2556819.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on August 2. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 2556819.

About Syneos Health
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Investor Relations Contact:                             
Ronnie Speight                                                    
Vice President, Investor Relations                       
+1 919 745 2745                                                  
investor.relations@syneoshealth.com                 

Press/Media Contact:
Danielle DeForge
Executive Director, External Communications
+1 781 425 2624
danielle.deforge@syneoshealth.com

Primary Logo


© GlobeNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNEOS HEALTH INC
08/24SYNEOS HEALTH : Greg Rush joins Parexel as Executive VP & CFO
AQ
08/21SYNEOS HEALTH : Acquires Kinapse to Further Enhance End-to-End Capabilities
AQ
08/21SYNEOS HEALTH : acquires consulting firm to boost regulatory, safety, pharmacovi..
AQ
08/21SYNEOS HEALTH : acquires advisory & operational solutions provider Kinapse
AQ
08/20SYNEOS HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
08/20Syneos Health™ Acquires Kinapse to Further Enhance End-to-End Capabilit..
GL
08/17Syneos Health to Present at the 2018 Baird Global Healthcare Conference
GL
08/17SYNEOS HEALTH : PAREXEL Announces Appointment of Two Key Executives
AQ
08/08SYNEOS HEALTH, INC. : Entry into a Material Definitive Agreement, Financial Stat..
AQ
08/08SYNEOS HEALTH : Announces Pricing of Secondary Offering of Common Stock
AQ
More news
News from SeekingAlpha
09/07Syneos Health (SYNH) Presents At Baird's Global Healthcare Conference - Slide.. 
09/07Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update 
08/20Syneos acquires Kinapse 
08/20Syneos acquires Kinapse 
08/07Syneos Health announces pricing of common stock offering 
Financials ($)
Sales 2018 4 452 M
EBIT 2018 516 M
Net income 2018 33,0 M
Debt 2018 2 581 M
Yield 2018 -
P/E ratio 2018 149,84
P/E ratio 2019 33,40
EV / Sales 2018 1,67x
EV / Sales 2019 1,49x
Capitalization 4 856 M
Chart SYNEOS HEALTH INC
Duration : Period :
Syneos Health Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNEOS HEALTH INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,2 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Alistair John Macdonald Chief Executive Officer & Director
Michael A. Bell Chairman
Jason Michael Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNEOS HEALTH INC9.75%4 856
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC27.75%25 338
LONZA GROUP20.13%24 487
INCYTE CORPORATION-28.11%14 247
SEATTLE GENETICS, INC.46.09%12 094